NCT04648930: Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies

Sponsor: Novartis Pharmaceuticals. Phase: . Conditions: Allergic Rhinitis